Table 3 Relationship between MPC1 expression and clinicopathological features of prostate cancer
From: MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer
Clinicopathologic | n | MPC1 expression | |||
|---|---|---|---|---|---|
Variable | Â | Positive | Weak positive | Negative | P value1 |
| Â | 88 | 29(32.95%) | 45(51.14%) | 14(15.91%) | Â |
Age(year) | Â | Â | Â | Â | 0.221 |
≤71 | 45 | 11(24.44%) | 26(57.78%) | 8(17.78%) |  |
>71 | 43 | 18(41.86%) | 19(44.19%) | 6(13.95%) | Â |
Gleason score | Â | Â | Â | Â | 0.682 |
<7 | 27 | 10(37.04%) | 14(51.85%) | 3(11.11%) | Â |
7–10 | 61 | 19(31.15%) | 31(50.82%) | 11(18.03%) |  |
PSA (ng/ml) | Â | Â | Â | Â | 0.715a |
≤10 | 10 | 4(40.00%) | 4(40.00%) | 2(20.00%) |  |
> 10 and ≤ 20 | 10 | 2(20.00%) | 6(60.00%) | 2(20.00%) |  |
> 20 | 68 | 23(33.8%) | 35(51.47%) | 10(14.71%) | Â |
UICC stage | Â | Â | Â | Â | 0.031 |
pT2 | 67 | 27(40.30%) | 31(46.27%) | 9(13.43%) | Â |
pT3-pT4 | 21 | 2(9.52%) | 14(66.67%) | 5(23.81%) | Â |
lymph node metastasis | Â | Â | Â | Â | 0.288 |
Negative | 74 | 24(32.43%) | 40(54.05%) | 10(13.51%) | Â |
Positive | 14 | 5(35.71%) | 5(35.71%) | 4(28.57%) | Â |
distant metastasis | Â | Â | Â | Â | 0.386 |
Negative | 63 | 19(30.16%) | 32(50.79%) | 12(19.05%) | Â |
Positive | 25 | 10(40.00%) | 13(52.00%) | 2(8.00%) | Â |